Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Strahlentherapie und Onkologie
Published in: Strahlentherapie und Onkologie 9/2017

01-09-2017 | Review Article

High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy

A systematic review

Authors: Georgios Chatzikonstantinou, Nikolaos Zamboglou, Claus Rödel, Eleni Zoga, Iosif Strouthos, Saeed Ahmed Butt, Nikolaos Tselis

Published in: Strahlentherapie und Onkologie | Issue 9/2017

Login to get access

Abstract

Purpose

To review the current status of interstitial high-dose-rate brachytherapy as a salvage modality (sHDR BRT) for locally recurrent prostate cancer after definitive radiotherapy (RT).

Materials and methods

A literature search was performed in PubMed using “high-dose-rate, brachytherapy, prostate cancer, salvage” as search terms. In all, 51 search results published between 2000 and 2016 were identified. Data tables were generated and summary descriptions created. The main outcome parameters used were biochemical control (BC) and toxicity scores.

Results

Eleven publications reported clinical outcome and toxicity with follow-up ranging from 4–191 months. A variety of dose and fractionation schedules were described, including 19.0 Gy in 2 fractions up to 42.0 Gy in 6 fractions. The 5‑year BC ranged from 18–77%. Late grade 3 genitourinary and gastrointestinal toxicity was 0–32% and 0–5.1%, respectively.

Conclusions

sHDR BRT appears as safe and effective salvage modality for the reirradiation of locally recurrent prostate cancer after definitive RT.
Literature
1.
Bruce JY, Lang JM, McNeel DG et al (2012) Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Onco 10:716–722
2.
Tran H, Kwok J, Pickles T et al (2014) Underutilization of local salvage therapy after radiation therapy for prostate cancer. Urol Oncol 32:701–706CrossRefPubMed
3.
Nguyen PL, D’Amico AV, Lee AK et al (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110:1417–1428CrossRefPubMed
4.
Nguyen PL, Alibhai, Shabbir MH, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Uro 67:825–836CrossRef
5.
Ward JF, Pagliaro LC, Pisters LL (2008) Salvage therapy for radiorecurrent prostate cancer. Curr Probl Cancer 32:242–271CrossRefPubMed
6.
Łyczek J, Kawczyńska MM, Garmol D et al (2009) HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer. J Contemp Brachytherapy 1:105–108PubMedPubMedCentral
7.
Jo Y, Fujii T, Hara R et al (2012) Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results. BJU Int 109:835–839CrossRefPubMed
8.
Tharp M, Hardacre M, Bennett R et al (2008) Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer. Brachytherapy 7:231–236CrossRefPubMed
9.
Yamada Y, Kollmeier MA, Pei X et al (2014) A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy 13:111–116CrossRefPubMed
10.
Chen CP, Weinberg V, Shinohara K et al (2013) Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5‑year outcomes. Int J Radiat Oncol Biol Phys 86:324–329CrossRefPubMed
11.
Kukiełka AM, Hetnał M, Dąbrowski T et al (2014) Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure. Strahlenther Onkol 190:165–170CrossRefPubMed
12.
Wojcieszek P, Szlag M, Głowacki G et al (2016) Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. Radiother Oncol 119:405–410CrossRefPubMed
13.
Hanna N, Hauswald H, Van T et al (2015) Long-term (10–15 year) results with high-dose-rate-(HDR) salvage therapy for recurrent prostate cancer. Brachytherapy 14:48CrossRef
14.
Oliai C, Yang L, Lee JY (2013) Prospective quality of life and efficacy of high-dose-rate brachytherapy salvage for recurrent prostate cancer. Int J Radiat Oncol Biol Phys 87:396CrossRef
15.
16.
Henríquez I, Sancho G, Hervás A et al (2014) Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity. Radiat Oncol 9:102CrossRefPubMedPubMedCentral
17.
American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035–1041
18.
Roach M, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974CrossRefPubMed
19.
20.
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346CrossRefPubMed
21.
22.
NRG/RTOG (2007) RTOG 0526: A prospective phase ii trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate adenocarcinoma following external beam radiotherapy. www.​rtog.​org. Accessed 10 March 2017
23.
Hoskin PJ, Colombo A, Henry A et al (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107:325–332CrossRefPubMed
24.
Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11:20–32CrossRefPubMed
25.
Baltas D, Zamboglou N, Sakelliou L (2007) The physics of modern brachytherapy for oncology. Series in medical physics and biomedical engineering. Taylor & Francis, Boca Raton
26.
Chung HT, D’Alimonte L, Loblaw A et al (2015) Quality of life (QOL) and acute toxicities of a pilot study of focal salvage high dose rate (HDR) prostate brachytherapy in patients with local recurrence after definitive external-beam radiotherapy (XRT). Brachytherapy 14:51CrossRef
27.
Guerif S, Didas O, Vallee M et al (2014) Focal salvage HDR brachytherapy for local prostate cancer recurrence after a primary radiation therapy: early experience of prospective study. Brachytherapy 13:116CrossRef
28.
Banerjee R, Park S, Anderson E et al (2015) From whole gland to hemigland to ultra-focal high-dose-rate prostate brachytherapy: a dosimetric analysis. Brachytherapy 14:366–372CrossRefPubMed
29.
Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424CrossRefPubMed
30.
Chade DC, Eastham J, Graefen M et al (2012) Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Uro 61:961–971CrossRef
31.
Mouraviev V, Spiess PE, Jones JS (2012) Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 61:1204–1211CrossRefPubMed
32.
Chalasani V, Martinez CH, Lim D et al (2009) Salvage HIFU for recurrent prostate cancer after radiotherapy. Prostate Cancer Prostatic Dis 12:124–129CrossRefPubMed
33.
Putora PM, Engeler D, Haile SR et al (2016) Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients. Strahlenther Onkol 192(3):182–189CrossRefPubMed
34.
Badakhshi H, Graf R, Budach V et al (2015) Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: An interim analysis of 312 cases. Strahlenther Onkol 191(4):303–309CrossRefPubMed
35.
Yoshioka Y, Suzuki O, Isohashi F et al (2016) High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8‑year follow-up. Int J Radiat Oncol Biol Phys 94:675–682CrossRefPubMed
36.
Hauswald H, Kamrava MR, Fallon JM et al (2016) High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys 94:667–674CrossRefPubMed
37.
Jawad MS, Dilworth JT, Gustafson GS et al (2016) Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys 94:657–666CrossRefPubMed
38.
Haie-Meder C, Siebert F, Pötter R (2011) Image guided, adaptive, accelerated, high dose brachytherapy as model for advanced small volume radiotherapy. Radiother Oncol 100:333–343CrossRefPubMed
39.
Meredith G, Wong D, Yaxley J et al (2016) The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 118(Suppl 3):49–55CrossRefPubMed
40.
Henkenberens C, von Klot CA, Ross TL et al (2016) (68) Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol 192(7):431–439CrossRefPubMed
41.
Demanes DJ, Ghilezan MI (2014) High-dose-rate brachytherapy as monotherapy for prostate cancer. Brachytherapy 13:529–541CrossRefPubMed
42.
Rutenberg MS, Meister M, Amin PP et al (2016) Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy. Brachytherapy 15:722–729CrossRefPubMed
43.
Fuller DB, Wurzer J, Shirazi R et al (2015) High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol 5:e615–23CrossRefPubMed
44.
Grills IS, Martinez AA, Hollander M et al (2004) High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 171:1098–1104CrossRefPubMed
45.
Yamada Y, Okihara K, Iwata T et al (2015) Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy. Asian J Androl 17:899–903CrossRefPubMedPubMedCentral
46.
Gomez-Veiga F, Mariño A, Alvarez L et al (2012) Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. BJU Int 109(Suppl 1):17–21CrossRefPubMed
Metadata
Title
High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy
A systematic review
Authors
Georgios Chatzikonstantinou
Nikolaos Zamboglou
Claus Rödel
Eleni Zoga
Iosif Strouthos
Saeed Ahmed Butt
Nikolaos Tselis
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 9/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1157-2

Other articles of this Issue 9/2017

Strahlentherapie und Onkologie 9/2017 Go to the issue

Original Article

Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma

Original Article

Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy

Case Study

A clinical example of extreme dose exposure for an implanted cardioverter–defibrillator

Original Article

125I brachytherapy in younger prostate cancer patients

Original Article

Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy

Literatur kommentiert

Radiotherapie verstärkt Wirkung von PD-1-Checkpoint-Inhibitoren